Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur

Not Applicable

Active, not recruiting

Conditions: Proximal Femoral Metastases

Interventions: Procedure: long-stem cemented hemiarthroplasty (LSCH)
Procedure: intramedullary nailing (IMN)
Behavioral: questionnaires

First Posted Date: 2014-06-16

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 73

Registration Number: NCT02164019

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States

and more 3 locations

Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation

Phase 2

Terminated

Conditions: Rectal Cancer
for Bowel Dysfunction Following Surgery for Rectal Cancers

Interventions: Device: Implantation of the InterStimTM
Behavioral: MSK BFI questionnaires
Behavioral: The Low Anterior Resection Score (LARS) questionnaires
Behavioral: The EuroQOL5D questionnaires
Behavioral: The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires

First Posted Date: 2014-06-13

Last Posted Date: 2018-02-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT02163187

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: Ruxolitinib
Drug: Erlotinib

First Posted Date: 2014-06-04

Last Posted Date: 2019-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT02155465

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Development of Psychotherapeutic Interventions for Parents Who Lost a Child

Not Applicable

Active, not recruiting

Conditions: Parents Who Have Lost a Child

Interventions: Behavioral: Meaning-Centered Grief Therapy (MCGT)
Behavioral: questionnaires assessments
Behavioral: Supportive Psychotherapy (SP)

First Posted Date: 2014-06-03

Last Posted Date: 2025-06-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT02153619

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

Phase 3

Completed

Conditions: Bladder Cancer

Interventions: Other: standard fluid management
Other: fluid management guided by the EV1000

First Posted Date: 2014-05-23

Last Posted Date: 2024-03-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 282

Registration Number: NCT02145871

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States

and more 2 locations

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Early Phase 1

Completed

Conditions: Thyroid Carcinoma

Interventions: Drug: Vemurafenib
Device: serial 124I PET/CT
Drug: thyrotropin alpha

First Posted Date: 2014-05-22

Last Posted Date: 2025-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT02145143

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Not Applicable

Completed

Conditions: Ovarian Cancer

Interventions: Procedure: PET/CT Scan
Procedure: MRI

First Posted Date: 2014-05-22

Last Posted Date: 2020-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT02144311

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Not Applicable

Withdrawn

Conditions: Histologically-confirmed Malignancies

Interventions: Radiation: [18F] FLT
Device: PET/CT scans

First Posted Date: 2014-05-15

Last Posted Date: 2019-09-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02139150

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: CMV Infection
Persistent CMV Viremia

Interventions: Biological: CMVpp65 Specific T-cells

First Posted Date: 2014-05-13

Last Posted Date: 2024-10-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 77

Registration Number: NCT02136797

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

Not Applicable

Active, not recruiting

Conditions: Cutaneous Basal Cell
Squamous Cell Carcinoma

Interventions: Radiation: Electronic Skin Surface Brachytherapy
Behavioral: Quality of life assessment

First Posted Date: 2014-05-06

Last Posted Date: 2025-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT02131805

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States

and more 5 locations

AI-Powered Research

Premium Access

Memorial Sloan Kettering Cancer Center

A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur

Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Development of Psychotherapeutic Interventions for Parents Who Lost a Child

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma